Frequently Asked Questions

Given a combination of economic and political factors, HLA previously predicted an uptick in the frequency and intensity of pharmacy audits in 2024. Unfortunately, HLA's predictions appear to be spot-on, and the information we are receiving from clients indicates that PBMs are terminating network pharmacies based on minor and inconsequential audit violations at a higher rate than ever before. In addition, a late December 2023 announcement from the Department of Health & Human Services ("OIG"), confirms that the "feds" are now prioritizing pharmacy audit enforcement.

OIG Oversees the Medicare & Medicaid Programs

OIG is one of the largest federal agencies and is responsible for maximizing the efficiency of government healthcare programs. Among other responsibilities, OIG ensures the programs operate efficiently by policing fraud, waste and abuse, including the submission of false claims, kickbacks for referrals, medical identity theft, and abuse in nursing homes.

Each year, OIG establishes priority areas for enforcement, with certain probes conducted by the Office of Audit Services. These efforts are publicized in OIG's Work Plan, which is updated monthly. OIG focuses on those areas it believes are most in need of attention.

OIG's 2024 Work Plan Prioritizes Inventory Audits

In December 2023, OIG updated its workplan to include "Audits of Pharmacy Support for Prescription Drug Event Data." When pharmacies submit claims for reimbursement, they are contained in a Prescription Drug Event (PDE) record that is relied on by the government and plan sponsors for adjudication. The PDE contains various data elements, including prescription drug costs and payment data that enables CMS to make Medicare and Medicaid payments.

Specifically, OIG announced that it will conduct audits to "determine whether PDE records were adequately supported by inventory purchases and complied with applicable Federal requirements." In other words, in addition to MCOs, PBMs, and CMS auditors, now a federal agency is planning to conduct inventory audits directly. Here is OIG's announcement:

Inventory Discrepancies are Mostly Trivial

HLA has published numerous articles on the defense of inventory audits, which you can access HERE and HERE. In summary, inventory shortfalls are commonplace due to the complexities of pharmacy practice. Accordingly, the federal government's focus on pharmacy inventory audits appears misguided.

For example, where is the compelling federal interest in whether a diabetic failed to pick-up his or her insulin? Or a patient had enough doses remaining on an inhaler to skip the refill? As a long-time, former public servant for the federal government, I always understood that the focus should be on the most meaningful and impactful issues. "Don't make a federal case out of it," is a saying for people blowing things out of proportion. Now, however, it seems the government is making a federal case out of trivial matters.

HLA Specializes in Audit Defense

Politics aside, the consequences of any type of failed audit can be severe, including recoupments, network sanctions, licensing board issues, and even criminal prosecution. Our experienced healthcare defense attorneys have a demonstrated track-record of highly successful outcomes in these cases, including the outright dismissal of criminal indictments and settlements for fractions of the claims paid with no licensing ramifications. Whether it be a PBM, payor, or OIG audit, our audit specialists are always available. Don't wait until your rights are jeopardized to pick up the phone.

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

Guidance for New Entrants on Navigating PBM Audit Complexities

New pharmacy owners face complex PBM audit requirements that demand strict documentation, accurate claims, and ongoing compliance. Establishing strong recordkeeping systems and proactive audit readiness can help prevent costly recoupments and protect long-term network participation.

Read More >>

How Pharmacies Can Challenge Unfair PBM Audit Findings

PBM audits can leave pharmacies facing exaggerated findings, steep recoupments, and even network termination. With the right strategies and legal support, pharmacies can successfully challenge unfair results and protect their business.

Read More >>

Top Red Flags That May Trigger a PBM Audit

PBM audits can be disruptive, costly, and often triggered by high prescription volumes, dispensing irregularities, or claim activity. Pharmacies can reduce risks through strong documentation, compliance, and legal support to challenge unfair findings and protect network status.

Read More >>

Approaching the Telehealth Policy Cliff: Medicare Telehealth Flexibilities to Expire Next Week

Without further congressional action, COVID-19 era telehealth flexibilities are set to expire on September 30, 2025. Read more to learn about what’s set to change and key guidance for telehealth providers to prepare to adapt to pre-pandemic coverage rules.

Read More >>